{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,4]],"date-time":"2026-11-04T08:58:21Z","timestamp":1793782701344,"version":"4.6.1"},"reference-count":39,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2023,9,26]],"date-time":"2023-09-26T00:00:00Z","timestamp":1695686400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2023,9,26]],"date-time":"2023-09-26T00:00:00Z","timestamp":1695686400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"name":"Fondazione IRCCS Istituto Nazionale dei Tumori"},{"DOI":"10.13039\/501100014382","name":"Ipsen","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100014382","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["BMC Cancer"],"abstract":"<jats:title>Abstract<\/jats:title><jats:sec>\n                <jats:title>Background<\/jats:title>\n                <jats:p>Well-differentiated (WD) neuroendocrine tumors (NETs) are a group of rare neoplasms with limited therapeutic options. Cabozantinib is an inhibitor of multiple tyrosine kinases with a pivotal role in NET pathogenesis, including c-MET and Vascular Endothelial Growth Factor Receptor 2 (VEGFR2). LOLA is the first prospective phase II trial aiming to assess the safety and activity of cabozantinib combined with lanreotide in WD NETs of gastroenteropancreatic (GEP), thoracic and of unknown origin.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Methods<\/jats:title>\n                <jats:p>This is a multicenter, open-label, double-cohort, non comparative, non-randomized, three-stage phase II trial. Eligible patients have to meet the following inclusion criteria: diagnosis of advanced or metastatic, progressive, non-functioning WD thoracic NETs, GEP-NETs or NETs of unknown origin with Ki67\u2009\u2265\u200910%; positive 68\u00a0Ga-PET uptake or somatostatin receptor 2 immunohistochemical (IHC) stain; maximum 1 prior systemic regimen for metastatic disease. Two cohorts will be considered: pNETs and carcinoids (typical or atypical lung and thymus NETs, gastro-intestinal NETs or NETs of unknown origin). In stage I, the primary objective is to find the optimal dose of cabozantinib in combination with lanreotide and to evaluate the safety of the combination (percentage of patients experiencing grade 3\u20135 toxicities according to NCI-CTCAE version 5.0). Starting dose of cabozantinib is 60\u00a0mg\/day continuously, plus lanreotide 120\u00a0mg every 28\u00a0days. In stage II and III, co-primary endpoints are safety and overall response rate (ORR) according to RECIST version 1.1. The uninteresting antitumor activity is fixed in ORR\u2009\u2264\u20095%. Secondary endpoints are progression-free survival and overall survival. Exploratory objectives include the assessment of c-MET, AXL and VEGFR2 IHC expression, to identify predictive or prognostic tissue biomarkers. Enrolment started in July 2020, with an expected trial duration of 42\u00a0months comprehensive of accrual, treatment and follow-up. Considering a drop-out rate of 5%, the maximum number of enrolled patients will be 69.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Discussion<\/jats:title>\n                <jats:p>Supported by a solid rationale, the trial has the potential to generate milestone data about the synergistic effects of cabozantinib plus lanreotide in a group of NET patients with relatively aggressive disease and limited therapeutic options.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Trial registration<\/jats:title>\n                <jats:p>LOLA is registered at ClinicalTrials.gov (NCT04427787) and EudraCT (2019\u2013004506-10).<\/jats:p>\n              <\/jats:sec>","DOI":"10.1186\/s12885-023-11287-2","type":"journal-article","created":{"date-parts":[[2023,9,26]],"date-time":"2023-09-26T15:03:45Z","timestamp":1695740625000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":16,"title":["Assessing the safety and activity of cabozantinib combined with lanreotide in gastroenteropancreatic and thoracic neuroendocrine tumors: rationale and protocol of the phase II LOLA trial"],"prefix":"10.1186","volume":"23","author":[{"given":"Francesca","family":"Corti","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Maria Pia","family":"Brizzi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Vito","family":"Amoroso","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dario","family":"Giuffrida","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Francesco","family":"Panzuto","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Davide","family":"Campana","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Natalie","family":"Prinzi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Massimo","family":"Milione","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tommaso","family":"Cascella","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Carlo","family":"Spreafico","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Giovanni","family":"Randon","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Simone","family":"Oldani","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rita","family":"Leporati","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Giulia","family":"Scotto","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Iolanda","family":"Pulice","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Benedetta Lombardi","family":"Stocchetti","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Luca","family":"Porcu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jorgelina","family":"Coppa","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Maria","family":"Di Bartolomeo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Filippo","family":"de Braud","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-5096-660X","authenticated-orcid":false,"given":"Sara","family":"Pusceddu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2023,9,26]]},"reference":[{"issue":"10","key":"11287_CR1","doi-asserted-by":"publisher","first-page":"1335","DOI":"10.1001\/jamaoncol.2017.0589","volume":"3","author":"A Dasari","year":"2017","unstructured":"Dasari A, Shen C, Halperin D, et al. Trends in the Incidence, Prevalence, and Survival Outcomes in Patients With Neuroendocrine Tumors in the United States. JAMA Oncol. 2017;3(10):1335\u201342.","journal-title":"JAMA Oncol"},{"issue":"3","key":"11287_CR2","doi-asserted-by":"publisher","first-page":"193","DOI":"10.1159\/000457957","volume":"105","author":"M Pavel","year":"2017","unstructured":"Pavel M, de Herder WW. ENETS Consensus Guidelines for the Standard of Care in Neuroendocrine Tumors. Neuroendocrinology. 2017;105(3):193\u20135.","journal-title":"Neuroendocrinology"},{"issue":"28","key":"11287_CR3","doi-asserted-by":"publisher","first-page":"4656","DOI":"10.1200\/JCO.2009.22.8510","volume":"27","author":"A Rinke","year":"2009","unstructured":"Rinke A, Muller H, Schade-Brittinger C, et al. Placebo-controlled, double-blind, prospective, randomized study on the effect of octreotide LAR in the control of tumor growth in patients with metastatic neuroendocrine midgut tumors: A report from the PROMID study group. J Clin Oncol. 2009;27(28):4656\u201363.","journal-title":"J Clin Oncol"},{"issue":"16","key":"11287_CR4","first-page":"1556","volume":"371","author":"ME Caplin","year":"2014","unstructured":"Caplin ME, Pavel M, Cwikla JB, et al. Lanreotide in metastatic enteropancreatic neuroendocrine tumors. N Engl J Med. 2014;371(16):1556\u20137.","journal-title":"N Engl J Med"},{"key":"11287_CR5","doi-asserted-by":"publisher","first-page":"196","DOI":"10.1159\/000457956","volume":"105","author":"A Perren","year":"2017","unstructured":"Perren A, Couvelard A, Scoazec JY, et al. ENETS consensus guidelines for the standards of care in neuroendocrine tumors: Pathology: diagnosis and prognostic stratification. Neuroendocrinology. 2017;105:196\u2013200.","journal-title":"Neuroendocrinology"},{"issue":"6","key":"11287_CR6","doi-asserted-by":"publisher","first-page":"501","DOI":"10.1056\/NEJMoa1003825","volume":"364","author":"E Raymond","year":"2011","unstructured":"Raymond E, Dahan L, Raoul JL, et al. Sunitinib malate for the treatment of pancreatic neuroendocrine tumors. N Engl J Med. 2011;364(6):501\u201313.","journal-title":"N Engl J Med"},{"issue":"9","key":"11287_CR7","doi-asserted-by":"publisher","first-page":"1987","DOI":"10.1093\/annonc\/mdv252","volume":"26","author":"E Grande","year":"2015","unstructured":"Grande E, Capdevila J, Castellano D, et al. Pazopanib in pretreated advanced neuroendocrine tumors: a phase II, open-label trial of the spanish task force group for neuroendocrine tumors (GETNE). Ann Oncol. 2015;26(9):1987\u201393.","journal-title":"Ann Oncol"},{"issue":"6","key":"11287_CR8","doi-asserted-by":"publisher","first-page":"695","DOI":"10.1016\/S1470-2045(15)70136-1","volume":"16","author":"AT Phan","year":"2015","unstructured":"Phan AT, Halperin DM, Chan JA, et al. Pazopanib and depot octreotide in advanced, well-differentiated neuroendocrine tumors: a multicentre, single-group, phase 2 study. Lancet Oncol. 2015;16(6):695\u2013703.","journal-title":"Lancet Oncol"},{"issue":"11","key":"11287_CR9","doi-asserted-by":"publisher","first-page":"1500","DOI":"10.1016\/S1470-2045(20)30496-4","volume":"21","author":"J Xu","year":"2020","unstructured":"Xu J, Shen L, Zhou Z, et al. Surufatinib in advanced extrapancreatic neuroendocrine tumours (SANET-ep): a randomised, double-blind, placebo-controlled, phase 3 study. Lancet Oncol. 2020;21(11):1500\u201312.","journal-title":"Lancet Oncol"},{"issue":"11","key":"11287_CR10","doi-asserted-by":"publisher","first-page":"1489","DOI":"10.1016\/S1470-2045(20)30493-9","volume":"21","author":"J Xu","year":"2020","unstructured":"Xu J, Shen L, Bai C, et al. Surufatinib in advanced pancreatic neuroendocrine tumours (SANET-p): a randomised, double-blind, placebo-controlled, phase 3 study. Lancet Oncol. 2020;21(11):1489\u201399.","journal-title":"Lancet Oncol"},{"issue":"20","key":"11287_CR11","doi-asserted-by":"publisher","first-page":"2304","DOI":"10.1200\/JCO.20.03368","volume":"39","author":"J Capdevila","year":"2021","unstructured":"Capdevila J, Fazio N, Lopez C, et al. Lenvatinib in Patients With Advanced Grade 1\/2 Pancreatic and Gastrointestinal Neuroendocrine Tumors: Results of the Phase II TALENT Trial (GETNE1509). J Clin Oncol. 2021;39(20):2304\u201312.","journal-title":"J Clin Oncol"},{"issue":"5","key":"11287_CR12","first-page":"S906","volume":"32","author":"R Garcia-Carbonero","year":"2021","unstructured":"Garcia-Carbonero R, Benavent M, Jim\u00e9nez Fonseca P, et al. The AXINET trial (GETNE1107): Axitinib plus octreotide LAR improves PFS by blinded central radiological assessment vs placebo plus octreotide LAR in G1\u20132 extrapancreatic NETs. Ann Oncol. 2021;32(5):S906\u201320.","journal-title":"Ann Oncol"},{"issue":"15","key":"11287_CR13","doi-asserted-by":"publisher","first-page":"4005","DOI":"10.1200\/JCO.2019.37.15_suppl.4005","volume":"37","author":"EK Bergsland","year":"2019","unstructured":"Bergsland EK, Mahoney MR, Asmis TR, et al. Prospective randomized phase II trial of pazopanib versus placebo in patients with progressive carcinoid tumors (CARC) (Alliance A021202). J Clin Oncol. 2019;37(15):4005\u20134005.","journal-title":"J Clin Oncol"},{"key":"11287_CR14","doi-asserted-by":"publisher","first-page":"228","DOI":"10.1200\/JCO.2017.35.4_suppl.228","volume":"35","author":"JA Chan","year":"2017","unstructured":"Chan JA, Faris JE, Murphy JE, et al. Phase II trial of cabozantinib in patients with carcinoid and pancreatic neuroendocrine tumors (pNET). J Clin Oncol. 2017;35:228.","journal-title":"J Clin Oncol"},{"issue":"7","key":"11287_CR15","doi-asserted-by":"publisher","first-page":"84","DOI":"10.1186\/s13098-015-0079-3","volume":"1","author":"B Murat Cde","year":"2015","unstructured":"Murat Cde B, da Rosa PW, Fortes MA, et al. Differential expression of genes encoding proteins of the HGF\/MET system in insulinomas. Diabetol Metab Syndr. 2015;1(7):84.","journal-title":"Diabetol Metab Syndr"},{"issue":"18 Pt 1","key":"11287_CR16","doi-asserted-by":"publisher","first-page":"6152","DOI":"10.1158\/1078-0432.CCR-04-0285","volume":"10","author":"DE Hansel","year":"2004","unstructured":"Hansel DE, Rahman A, House M, et al. Met proto-oncogene and insulin-like growth factor binding protein 3 overexpression correlates with metastatic ability in well-differentiated pancreatic endocrine neoplasms. Clin Cancer Res. 2004;10(18 Pt 1):6152\u20138.","journal-title":"Clin Cancer Res"},{"issue":"7","key":"11287_CR17","first-page":"2273","volume":"8","author":"PL Peghini","year":"2002","unstructured":"Peghini PL, Iwamoto M, Raffeld M, et al. Overexpression of epidermal growth factor and hepatocyte growth factor receptors in a proportion of gastrinomas correlates with aggressive growth and lower curability. Clin Cancer Res. 2002;8(7):2273\u201385.","journal-title":"Clin Cancer Res"},{"issue":"16","key":"11287_CR18","doi-asserted-by":"publisher","first-page":"4464","DOI":"10.1073\/pnas.1600007113","volume":"113","author":"GW Krampitz","year":"2016","unstructured":"Krampitz GW, George BM, Willingham SB, et al. Identification of tumorigenic cells and therapeutic targets in pancreatic neuroendocrine tumors. Proc Natl Acad Sci U S A. 2016;113(16):4464\u20139.","journal-title":"Proc Natl Acad Sci U S A"},{"issue":"11","key":"11287_CR19","doi-asserted-by":"publisher","first-page":"1702","DOI":"10.5858\/2009-0664-OAR1.1","volume":"134","author":"J Song","year":"2010","unstructured":"Song J, Li M, Tretiakova M, et al. Expression patterns of PAX5, c-Met, and paxillin in neuroendocrine tumors of the lung. Arch Pathol Lab Med. 2010;134(11):1702\u20135.","journal-title":"Arch Pathol Lab Med"},{"key":"11287_CR20","doi-asserted-by":"publisher","first-page":"98","DOI":"10.1016\/j.pharmthera.2015.05.007","volume":"152","author":"U Rai","year":"2015","unstructured":"Rai U, Thrimawithana TR, Valery C, Young SA. Therapeutic uses of somatostatin and its analogues: Current view and potential applications. Pharmacol Ther. 2015;152:98\u2013110.","journal-title":"Pharmacol Ther"},{"issue":"3","key":"11287_CR21","first-page":"115","volume":"25","author":"M Chalabi","year":"2014","unstructured":"Chalabi M, Duluc C, Caron P, et al. Somatostatin analogs: does pharmacology impact antitumor efficacy? Endocrinol Metab. 2014;25(3):115\u201327.","journal-title":"Endocrinol Metab"},{"issue":"42","key":"11287_CR22","doi-asserted-by":"publisher","first-page":"40601","DOI":"10.1074\/jbc.M306510200","volume":"278","author":"S Pola","year":"2003","unstructured":"Pola S, Cattaneo MG. Vicentini LM Anti-migratory and anti-invasive effect of somatostatin in human neuroblastoma cells: involvement of Rac and MAP kinase activity. J Biol Chem. 2003;278(42):40601\u20136.","journal-title":"J Biol Chem"},{"issue":"19","key":"11287_CR23","doi-asserted-by":"publisher","first-page":"3110","DOI":"10.1007\/s00018-008-8418-2","volume":"65","author":"R Azar","year":"2008","unstructured":"Azar R, Najib S, Lahlou H, et al. Phosphatidylinositol 3-kinase-dependent transcriptional silencing of the translational repressor 4E-BP1. Cell Mol Life Sci. 2008;65(19):3110\u20137.","journal-title":"Cell Mol Life Sci"},{"issue":"12","key":"11287_CR24","doi-asserted-by":"publisher","first-page":"834","DOI":"10.1038\/nrm3012","volume":"11","author":"L Trusolino","year":"2010","unstructured":"Trusolino L, Bertotti A, Comoglio PM, et al. MET signalling: principles and functions in development, organ regeneration and cancer. Nat Rev Mol Cell Biol. 2010;11(12):834\u201348.","journal-title":"Nat Rev Mol Cell Biol"},{"key":"11287_CR25","doi-asserted-by":"publisher","first-page":"49","DOI":"10.1016\/j.pharmthera.2017.07.006","volume":"181","author":"C Neuzillet","year":"2018","unstructured":"Neuzillet C, de Mestier L, Rousseau B, et al. Unravelling the pharmacologic opportunities and future directions for targeted therapies in gastro-intestinal cancers part 2: Neuroendocrine tumours, hepatocellular carcinoma, and gastro-intestinal stromal tumours. Pharmacol Ther. 2018;181:49\u201375.","journal-title":"Pharmacol Ther"},{"issue":"Suppl 1","key":"11287_CR26","doi-asserted-by":"publisher","first-page":"S68","DOI":"10.1016\/j.dld.2003.11.020","volume":"36","author":"D Ferone","year":"2004","unstructured":"Ferone D, van Hagen PM, Semino C, et al. Somatostatin receptor distribution and function in immune system. Dig Liver Dis. 2004;36(Suppl 1):S68-77.","journal-title":"Dig Liver Dis"},{"issue":"4","key":"11287_CR27","doi-asserted-by":"publisher","first-page":"460","DOI":"10.1016\/j.coph.2008.05.001","volume":"8","author":"M Levite","year":"2008","unstructured":"Levite M. Neurotransmitters activate T-cells and elicit crucial functions via neurotransmitter receptors. Curr Opin Pharmacol. 2008;8(4):460\u201371.","journal-title":"Curr Opin Pharmacol"},{"issue":"12","key":"11287_CR28","doi-asserted-by":"publisher","first-page":"294","DOI":"10.1186\/s12967-014-0294-y","volume":"13","author":"AR Kwilas","year":"2014","unstructured":"Kwilas AR, Ardiani A, Donahue RN, Aftab DT, Hodge JW. Dual effects of a targeted small-molecule inhibitor (cabozantinib) on immune-mediated killing of tumor cells and immune tumor microenvironment permissiveness when combined with a cancer vaccine. J Transl Med. 2014;13(12):294.","journal-title":"J Transl Med"},{"issue":"4","key":"11287_CR29","doi-asserted-by":"publisher","first-page":"379","DOI":"10.1055\/s-0038-1673621","volume":"38","author":"YY Lin","year":"2018","unstructured":"Lin YY, Tan CT, Chen CW, et al. Immunomodulatory Effects of Current Targeted Therapies on Hepatocellular Carcinoma: Implication for the Future of Immunotherapy. Semin Liver Dis. 2018;38(4):379\u201388.","journal-title":"Semin Liver Dis"},{"issue":"15","key":"11287_CR30","doi-asserted-by":"publisher","first-page":"4501","DOI":"10.1200\/jco.2014.32.15_suppl.4501","volume":"32","author":"A Borghese Apolo","year":"2014","unstructured":"Borghese Apolo A, Tomita Y, Lee MJ, et al. Effect of cabozantinib on immunosuppressive subsets in metastatic urothelial carcinoma. J Clin Oncol. 2014;32(15):4501\u20134501.","journal-title":"J Clin Oncol"},{"issue":"15","key":"11287_CR31","doi-asserted-by":"publisher","first-page":"1093","DOI":"10.1200\/JCO.2016.34.15_suppl.1093","volume":"34","author":"DG Duda","year":"2016","unstructured":"Duda DG, Zieh DR, Guo H, et al. Effect of cabozantinib treatment on circulating immune cell populations in patients with metastatic triple-negative breast cancer (TNBC). J Clin Oncol. 2016;34(15):1093\u20131093.","journal-title":"J Clin Oncol"},{"issue":"2","key":"11287_CR32","doi-asserted-by":"publisher","first-page":"228","DOI":"10.1016\/j.ejca.2008.10.026","volume":"42","author":"EA Eisenhauer","year":"2009","unstructured":"Eisenhauer EA, Therasse P, Bogaerts J, et al. New response evaluation criteria in solid tumours: revised RECIST guideline (version 1.1). Eur J Cancer. 2009;42(2):228\u201347.","journal-title":"Eur J Cancer"},{"issue":"Suppl 2","key":"11287_CR33","first-page":"S219","volume":"31","author":"EP Krenning","year":"1999","unstructured":"Krenning EP, Valkema R, Kooij PP, et al. Scintigraphy and radionuclide therapy with [indium-111-labelled-diethyl triamine penta-acetic acid-D-Phe1]-octreotide. Ital J Gastroenterol Hepatol. 1999;31(Suppl 2):S219\u201323.","journal-title":"Ital J Gastroenterol Hepatol"},{"issue":"11","key":"11287_CR34","doi-asserted-by":"publisher","first-page":"1172","DOI":"10.1038\/modpathol.3800954","volume":"20","author":"M Volante","year":"2007","unstructured":"Volante M, Brizzi MP, Faggiano A, et al. Somatostatin receptor type 2A immunohistochemistry in neuroendocrine tumors: a proposal of scoring system correlated with somatostatin receptor scintigraphy. Mod Pathol. 2007;20(11):1172\u201382.","journal-title":"Mod Pathol"},{"issue":"1","key":"11287_CR35","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1016\/0197-2456(89)90015-9","volume":"10","author":"R Simon","year":"1989","unstructured":"Simon R. Optimal two-stage designs for phase II clinical trials. Control Clin Trials. 1989;10(1):1\u201310.","journal-title":"Control Clin Trials"},{"issue":"19","key":"11287_CR36","doi-asserted-by":"publisher","first-page":"1814","DOI":"10.1056\/NEJMoa1510016","volume":"373","author":"TK Choueiri","year":"2015","unstructured":"Choueiri TK, Escudier B, Powles T, et al. Cabozantinib versus Everolimus in Advanced Renal-Cell Carcinoma. N Engl J Med. 2015;373(19):1814\u201323.","journal-title":"N Engl J Med"},{"issue":"6","key":"11287_CR37","doi-asserted-by":"publisher","first-page":"591","DOI":"10.1200\/JCO.2016.70.7398","volume":"35","author":"TK Choueiri","year":"2017","unstructured":"Choueiri TK, Halabi S, Sanford BL, et al. Cabozantinib Versus Sunitinib As Initial Targeted Therapy for Patients With Metastatic Renal Cell Carcinoma of Poor or Intermediate Risk: The Alliance A031203 CABOSUN Trial. J Clin Oncol. 2017;35(6):591\u20137.","journal-title":"J Clin Oncol"},{"issue":"29","key":"11287_CR38","doi-asserted-by":"publisher","first-page":"3639","DOI":"10.1200\/JCO.2012.48.4659","volume":"31","author":"R Elisei","year":"2013","unstructured":"Elisei R, Schlumberger MJ, M\u00fcller SP, et al. Cabozantinib in progressive medullary thyroid cancer. J Clin Oncol. 2013;31(29):3639\u201346.","journal-title":"J Clin Oncol"},{"issue":"1","key":"11287_CR39","doi-asserted-by":"publisher","first-page":"54","DOI":"10.1056\/NEJMoa1717002","volume":"379","author":"GK Aboualfa","year":"2018","unstructured":"Aboualfa GK, Meyer T, Cheng AL, et al. Cabozantinib in Patients with Advanced and Progressing Hepatocellular Carcinoma. N Engl J Med. 2018;379(1):54\u201363.","journal-title":"N Engl J Med"}],"container-title":["BMC Cancer"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12885-023-11287-2.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s12885-023-11287-2\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12885-023-11287-2.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,11,19]],"date-time":"2023-11-19T00:10:40Z","timestamp":1700352640000},"score":1,"resource":{"primary":{"URL":"https:\/\/bmccancer.biomedcentral.com\/articles\/10.1186\/s12885-023-11287-2"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,9,26]]},"references-count":39,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2023,12]]}},"alternative-id":["11287"],"URL":"https:\/\/doi.org\/10.1186\/s12885-023-11287-2","relation":{},"ISSN":["1471-2407"],"issn-type":[{"value":"1471-2407","type":"electronic"}],"subject":[],"published":{"date-parts":[[2023,9,26]]},"assertion":[{"value":"8 September 2022","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"9 August 2023","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"26 September 2023","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The study protocol was approved by the Ethics Committee of the Fondazione IRCCS Istituto Nazionale dei Tumori di Milano (INT 240\/19, v.1.1 21\/10\/2019) and by local Committees of participating Centers. The trial has been registered in EudraCT database (2019\u2013004506-10) and at clinicaltrials.gov (NCT04427787). This study will be conducted in full conformance with the ICH E6\/GCP guidelines and the principles of the Declaration of Helsinki. All study participants will provide their voluntary written informed consent before performance of any study-related procedure not part of normal medical care, with the understanding that consent may be withdrawn by the subject at any time without prejudice to future medical care. Any protocol amendments will be prepared by the Sponsor and submitted to the IRB\/EC and to regulatory authorities in accordance with local regulatory requirements. If an amendment substantially alters the study design or increases the potential risk to the participant, patients will be re-consented to the most current version of the Consent Forms or to a significant addendum in accordance to IRB\/IEC policy and applicable laws. The Sponsor maintains confidentiality standards by coding each patient through assignment of a unique patient identification number. Each participating Investigator is responsible for ensuring data quality. Patient medical information obtained by this study is confidential and may only be disclosed to third parties as permitted by the Informed Consent Form (or separate authorization for use and disclosure of personal health information) signed by the patient, unless permitted or required by law. Data generated by this study must be available for inspection upon request by representatives of the national and local health authorities, Sponsor\u2019s monitors, representatives, and collaborators, and the IRB\/EC for each study site, as appropriate. The Sponsor provides an insurance policy in case patients suffer harm from trial participation.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"Not applicable.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"Dr. Pusceddu reported receiving honoraria from Novartis, Ipsen, Pfizer, Merck Serono, and Advanced Accelerator Applications (AAA); receiving grants from Ipsen and Pfizer; and receiving personal fees from AAA, Novartis, and Merck outside the submitted work. Dr. Prinzi reported receiving honoraria and travel accommodations from Novartis, Ipsen, Pfizer, Merck Serono, and Italfarmaco and receiving personal fees from Merck outside the submitted work. Dr. Panzuto reported receiving honoraria for speaker and advisory roles from Novartis, for an advisory role from Ipsen, and for consulting from AAA and receiving travel accommodations from Pfizer. Dr. Corti reported receiving nonfinancial support from AAA and Ipsen outside the submitted work. Dr. Porcu reported receiving honoraria for consulting from Ipsen and Italfarmaco. Dr. de Braud reported receiving honoraria for serving on advisory boards or speakers bureaus for Amgen, Novartis, Roche, Incyte, EMD Serono, Bristol Myers Squibb, Roche, Pfizer, Menarini, Sanofi, Healthcare Research & Pharmacoepidemiology, and Dephaforum; receiving research funding from Novartis, Roche, Merck Sharp & Dohme, Merck Serono, Pfizer, Servier, and Nerviano Medical Sciences; and receiving honoraria and\/or personal fees from Roche, EMD Serono, Nerviano Medical Sciences, Sanofi, MSD, Novartis, Incyte, Bristol Myers Squibb, Menarini, Merck, Pfizer, Healthcare Research & Pharmacoloepidemiology, Servier, Amgen, and Dephaforum outside the submitted work. No other disclosures were reported.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"908"}}